Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.
Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback
by Arpita Dutt
Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.
Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.
KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Gilead Sciences (GILD)
by Kevin Cook
Could a transformational M&A deal reverse the 18-month slide in sales and profits?
Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
by Arpita Dutt
Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.
Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Galapagos Initiates 3 Phase II Studies for Filgotinib
by Zacks Equity Research
Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.
New Strong Sell Stocks for March 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
by Arpita Dutt
Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.
Mylan Receives Tentative Approval from FDA for HIV Therapy
by Zacks Equity Research
Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).
Biotech Bull Making a Comeback
by Kevin Cook
A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
by Arpita Dutt
The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.
Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
by Zacks Equity Research
At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.
Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
by Zacks Equity Research
We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
by Arpita Dutt
Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.
Is This the Right Time to Invest in Biotech Stocks?
by Arpita Dutt
The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?